Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
August 07, 2023 07:00 ET
|
Ikena Oncology, Inc.
Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena’s targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO,...
Ikena Oncology to Participate in Upcoming Investor Conferences
May 24, 2023 08:00 ET
|
Ikena Oncology, Inc.
BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline
May 15, 2023 07:50 ET
|
Ikena Oncology, Inc.
Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date Preclinical data at AACR Annual Meeting...
Ikena Oncology Announces $40 Million Underwritten Offering
May 15, 2023 07:45 ET
|
Ikena Oncology, Inc.
BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, announced...
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 20, 2023 08:00 ET
|
Ikena Oncology, Inc.
BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting
April 17, 2023 09:00 ET
|
Ikena Oncology, Inc.
IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling IK-930’s differentiated paralog selectivity and robust repressor activity in...
Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
March 14, 2023 07:00 ET
|
Ikena Oncology, Inc.
Focused targeted oncology pipeline advancing towards multiple near-term milestones; runway into 2025 Novel paralog-selective TEAD inhibitor, IK-930, advanced through multiple dose escalation...
Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting
March 07, 2023 08:00 ET
|
Ikena Oncology, Inc.
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma
March 06, 2023 08:00 ET
|
Ikena Oncology, Inc.
BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference
February 28, 2023 08:00 ET
|
Ikena Oncology, Inc.
BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...